How to Run a Clinical AI Postmarket Performance Review Meeting
A practitioner’s guide to structuring the meeting: required inputs, roles, cadence, escalation, and audit-ready documentation.
Why a Structured Postmarket Review Meeting Matters
A clinical AI postmarket performance review meeting is the recurring governance forum where clinical, technical, and regulatory stakeholders jointly examine how a deployed AI or machine learning model is performing in real-world use and decide whether continued use, modification, or escalation is warranted. Healthcare organizations deploying AI-enabled software as a medical device or clinical decision support tools carry an ongoing obligation to monitor performance after deployment, not just validate it before release.
Without a structured meeting process, postmarket monitoring tends to fragment. Technical teams track drift metrics in isolation, clinical teams route adverse events through separate incident channels, and no single forum connects the two to a documented governance decision. Treating the review meeting as a defined control point, with fixed inputs, defined participants, and a documented decision record, closes that gap.
The rest of this guide describes how to structure that meeting: what data should feed it, who needs to be in the room, how cadence and escalation should be set, and what documentation is needed to support later audit or inspection.
Core Elements of a Postmarket Review Meeting
Four elements keep the review defensible and repeatable across model versions and risk tiers.
| Element | Purpose |
|---|---|
| Structured inputs | Performance metrics, drift indicators, and adverse event data compiled before the meeting |
| Cross-functional roles | Clinical, technical, and regulatory stakeholders with defined responsibilities |
| Fixed cadence and triggers | Scheduled reviews plus threshold-based escalation triggers |
| Documented decisions | A decision log linking findings to actions, owners, and deadlines |
Who Should Be in the Room
Attendance should reflect the decisions the meeting is expected to make. The following roles cover clinical safety, technical interpretation, regulatory judgment, governance ownership, and platform integrity.
| Role | Responsibility in the review |
|---|---|
| Clinical lead or medical safety officer | Interprets clinical outcome and adverse event data and assesses patient safety implications of any observed performance change. |
| Data science or ML engineering representative | Presents drift, calibration, and performance telemetry and explains likely technical causes of observed changes. |
| Quality and regulatory affairs | Determines whether findings trigger reporting obligations or intersect with change control requirements. |
| Governance committee chair | Owns the meeting structure, ensures required inputs were reviewed, and confirms decisions are documented. |
| IT, security, or platform owner | Confirms monitoring data integrity and flags any infrastructure or configuration changes affecting model behavior. |
Required Inputs for the Review
Inputs should be assembled before the meeting so discussion focuses on interpretation and decision-making, not data gathering.
- Model performance metrics tracked against an established baseline for the review period
- Drift indicators, distinguishing data drift (input distribution shift) from performance drift (output accuracy degradation)
- Data quality flags from the monitoring pipeline, such as missing fields or upstream schema changes
- Adverse event and complaint data with potential AI model involvement, cross-referenced against clinical incident reports
- Model version, training data snapshot, and deployment environment records for the period under review
- Status of open action items and decisions from the previous review meeting
Setting Review Cadence and Escalation Triggers
The meeting cadence should be fixed in advance and tied to a documented, risk-based rationale rather than set arbitrarily. Higher-risk clinical models, or those with limited real-world deployment history, generally warrant more frequent scheduled review than mature, lower-risk tools.
Scheduled cadence should be kept distinct from ad hoc, threshold-triggered reviews. A monitoring plan should define specific alerting thresholds, for example a drift metric or adverse event rate crossing a defined limit, that trigger an off-cycle review independent of the regular schedule. Conflating routine periodic governance review with continuous monitoring alerts makes it harder to demonstrate that both mechanisms are functioning as intended.
Organizations should document the rationale for their chosen cadence and the specific conditions that trigger an ad hoc review, since no universal cadence requirement applies uniformly across all clinical AI use cases. This distinction also clarifies accountability: routine reviews confirm ongoing acceptable performance, while triggered reviews respond to a specific signal that performance may have already changed.
Documentation Practices That Support Audit Readiness
The defensibility of the meeting rests as much on the record as on the discussion. Useful documentation practices include:
- Use a standardized decision log capturing findings, the decision reached, the responsible owner, and a deadline for every review
- Record which specific data, including metrics, time window, and model version, informed each decision, not just the conclusion reached
- Maintain audit logs of who reviewed which data and when, kept separately from the decision log itself
- Distinguish routine performance review decisions from formal change control actions in the record
- Retain records in a form that allows the full review history for a given model version to be reconstructed on request
Regulatory Context to Verify Before Finalizing Your Process
Predetermined change control plans for AI and machine learning-based software are a recognized regulatory concept, but their exact scope, required cadence, and documentation expectations vary and should be confirmed with regulatory and legal counsel rather than assumed. The same applies to specific postmarket surveillance obligations that may attach to a given clinical AI deployment.
What is consistent across frameworks is that the defensibility of a postmarket review rests on the underlying telemetry and records available when questioned, not on the meeting alone. Runtime governance capabilities that provide continuous monitoring, policy enforcement, and audit logging for AI systems can supply the drift metrics, performance data, and access records these reviews depend on.
Trussed AI provides runtime governance and security for enterprise AI systems, including runtime monitoring and audit logging that can support the evidence base for a postmarket review process. The clinical and regulatory judgment applied within the meeting itself remains a governance and clinical responsibility that no monitoring tool can substitute for.
A clinical AI postmarket performance review meeting is a recurring, cross-functional governance session that examines model drift, performance metrics, data quality issues, and adverse events tied to a deployed clinical AI system, and produces a documented decision on whether to continue, modify, restrict, or escalate its use.
Build the Runtime Foundation Behind Your Postmarket Reviews
A structured review meeting depends on reliable, auditable telemetry. See how runtime governance supports the monitoring and audit logging behind defensible postmarket surveillance.
Explore Runtime Governance